IPHA

Innate Pharma SA

Add to Watchlist

Advanced Chart

1.820

0(0.000%)1D

Line

Candle

YTD

High

1.820

Open

1.820

VWAP

1.82

Vol

10.41K

Mkt Cap

167.78M

Low

1.820

Amount

18.94K

EV/EBITDA(TTM)

Total Shares

80.95M

156.37M

EV/OCF(TTM)

P/S(TTM)

22.51

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2020Q4

27.11M

+103.36%

0.000

-100%

Estimates Revision

The market is revising Downward the revenue expectations for Innate Pharma S.A. (IPHA) for FY2025, with the revenue forecasts being adjusted by -80.26% over the past three months. During the same period, the stock price has changed by -16.35%.

Revenue Estimates for FY2025

Revise Downward

-80.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-186.66%

In Past 3 Month

Stock Price

Go Down

-16.35%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast IPHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IPHA is 6.00 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

Current: 1.820

Low

2.00

Averages

6.00

High

8.00

Current: 1.820

Low

2.00

Averages

6.00

High

8.00

H.C. Wainwright

Neutral -> Buy

upgrade

2025-10-29

Reason

H.C. Wainwright

Price Target

2025-10-29

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Innate Pharma to Buy from Neutral with a $5 price target. The company announced its intention to file an application with the FDA for an accelerated approval of lacutamab and initiate a Phase 3 study to evaluate the drug as a therapy for cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm recommends buying the stock's recent weakness.

Lucid Capital

NULL

Buy

initiated

2025-10-23

Reason

Lucid Capital

Price Target

2025-10-23

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Innate Pharma with a Buy rating and $8 price target. Innate is a clinical-stage biotechnology company focused on developing antibodies and antibody-drug conjugates for oncology indications, the analyst tells investors in a research note. The firm believes the company's IPH4502 could serve a "key niche" in Padcev-pretreated metastatic urothelial carcinoma, a $1.5B peak sales opportunity.

H.C. Wainwright

Buy -> Neutral

downgrade

2025-09-18

Reason

H.C. Wainwright

Price Target

2025-09-18

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Innate Pharma to Neutral from Buy without a price target. The company is prioritizing three assets, IP4502, lacutamab, and monalizumab, which do not have meaningful catalysts in the next 12 months, the analyst tells investors in a research note. The firm believes a "financing overhang is imminent" if Innate is unable to identify a partner for lacutamab development nor able monetize any of its assets.

Leerink

Outperform -> Market Perform

downgrade

$10 -> $2

2025-09-17

Reason

Leerink

Price Target

$10 -> $2

2025-09-17

downgrade

Outperform -> Market Perform

Reason

Leerink downgraded Innate Pharma to Market Perform from Outperform with a price target of $2, down from $10. The company relegating their proprietary antibody-based NK cell engager therapeutic platform to the background overly concentrates Innate's outlook to an antibody-drug conjugate strategy, which has an uncertain timing on generating clinical proof-of-concept outcomes, the analyst tells investors in a research note. Leerink adds that the lack of success in finding a partner to co-develop lacutamab and looming financing overhang reduces the firm's confidence in upside for the stock next year.

BTIG

Justin Zelin

Buy

initiated

2025-07-28

Reason

BTIG

Justin Zelin

Price Target

2025-07-28

initiated

Buy

Reason

BTIG analyst Justin Zelin initiated coverage of Innate Pharma with a Buy rating and $8 price target. Innate is a clinical-stage biotechnology company developing therapies for cancer and autoimmune disease, the analyst tells investors in a research note. The firm believes IPH4502 could address post Padcev treated bladder cancer patients and other Nectin-4 low tumor types. It sees the Initial Phase 1 data in late 2025 or early 2026 as a catalyst for the shares.

H.C. Wainwright

Buy

maintain

$11

2025-04-24

Reason

H.C. Wainwright

Price Target

$11

2025-04-24

maintain

Buy

Reason

H.C. Wainwright lowered the firm's price target on Innate Pharma to $11 from $11.50 and keeps a Buy rating on the shares. The firm postponed the U.S. launch of IPH6101 to 2029 from previously estimated 2027 and EU launch to 2030 from 2028.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Innate Pharma SA (IPHA.O) is -3.58, compared to its 5-year average forward P/E of -2.69. For a more detailed relative valuation and DCF analysis to assess Innate Pharma SA 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.69

Current PE

-3.58

Overvalued PE

10.00

Undervalued PE

-15.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.72

Current EV/EBITDA

-4.75

Overvalued EV/EBITDA

-2.74

Undervalued EV/EBITDA

-8.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.10

Current PS

1.56

Overvalued PS

5.62

Undervalued PS

2.59